Conference Coverage
Commentary
Powerful breast-implant testimony constrained by limited evidence
SILVER SPRING, MD. – Women report personal horror stories of apparent breast-implant complications, but systematically-collected data remain...
Conference Coverage
Whole-genome sequencing demonstrates clinical relevance
GLASGOW – A study comparing whole-genome sequencing (WGS) with fluorescence in situ hybridization showed that the WGS was reliable and clinically...
Conference Coverage
ONC’s Dr. Rucker: Era of provider-controlled data is over
WASHINGTON – Interoperability going forward means putting the power in the hands of the patients, according to the government’s top health data...
Conference Coverage
Novel chemo/PARP inhibitor strategy promising for advanced pancreatic cancer
ATLANTA – Investigators are treating patients with advanced pancreatic cancer and homologous recombination deficiencies with a novel strategy of...
Conference Coverage
UNITY-NHL: Interim findings show activity, tolerability of umbralisib for R/R MZL
ATLANTA – The phosphoinositide 3-kinase delta inhibitor is active as a single-agent therapy in patients with relapsed or refractory marginal zone...
Conference Coverage
Genetic variant increases stroke risk in childhood cancer survivors
ATLANTA - Dr. Yadav Sapkota of St. Jude Children's Research Hospital discusses the identification of a genetic variant that is strongly associated...
Conference Coverage
Anti-EGFR TKI, MET inhibitor team up against drug-resistant NSCLC
ATLANTA – Dr. Lecia Sequist discusses early results from the TATTON trial, which is evaluating osimertinib plus...
Conference Coverage
CAR T cells target HER2 expression in advanced sarcomas
ATLANTA – Although HER2 expression in osteosarcoma and rhabomyosarcoma is too low for HER2-targeted therapies such...
Conference Coverage
Consider 9-mm surgical margins for MIS
WAIKOLOA, HAWAII – The widely utilized 5-mm surgical margins for excision of melanoma in situ are inadequate.
Conference Coverage
Ticagrelor reversal agent looks promising
NEW ORLEANS – Ticagrelor’s antiplatelet effect was squelched within 5 minutes.